356 related articles for article (PubMed ID: 11145251)
21. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fisher DE
Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):47-51. PubMed ID: 11893035
[TBL] [Abstract][Full Text] [Related]
22. Comparative immunoreactivity of CD-68 and HMB-45 in malignant melanoma, neural tumors and nevi.
Shah IA; Gani OS; Wheler L
Pathol Res Pract; 1997; 193(7):497-502. PubMed ID: 9342756
[TBL] [Abstract][Full Text] [Related]
23. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas.
Vachtenheim J; Novotná H
Cell Mol Biol (Noisy-le-grand); 1999 Nov; 45(7):1075-82. PubMed ID: 10644012
[TBL] [Abstract][Full Text] [Related]
24. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous desmoplastic melanoma.
Busam KJ
Adv Anat Pathol; 2005 Mar; 12(2):92-102. PubMed ID: 15731577
[TBL] [Abstract][Full Text] [Related]
26. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
27. Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.
Shanesmith RP; Smart C; Cassarino DS
Am J Dermatopathol; 2011 Oct; 33(7):663-8. PubMed ID: 21915031
[TBL] [Abstract][Full Text] [Related]
28. Nevi, other than dysplastic and Spitz nevi.
Cochran AJ; Bailly C; Paul E; Dolbeau D
Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
[TBL] [Abstract][Full Text] [Related]
29. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
30. MITF accurately highlights epidermal melanocytes in atypical intraepidermal melanocytic proliferations.
Nybakken GE; Sargen M; Abraham R; Zhang PJ; Ming M; Xu X
Am J Dermatopathol; 2013 Feb; 35(1):25-9. PubMed ID: 22668579
[TBL] [Abstract][Full Text] [Related]
31. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
32. Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Rao Q; Wang Y; Xia QY; Shi SS; Shen Q; Tu P; Shi QL; Zhou XJ; Wu B
Int J Clin Exp Pathol; 2014; 7(3):1132-9. PubMed ID: 24696729
[TBL] [Abstract][Full Text] [Related]
33. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
34. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
35. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
37. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
38. Microphthalmia transcription factor: a specific marker for malignant melanoma.
Vachtenheim J; Borovanský J
Prague Med Rep; 2004; 105(3):318-24. PubMed ID: 15782558
[TBL] [Abstract][Full Text] [Related]
39. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).
Medic S; Ziman M
PLoS One; 2010 Apr; 5(4):e9977. PubMed ID: 20421967
[TBL] [Abstract][Full Text] [Related]
40. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
